Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS: We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. RESULTS: A primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P<0.001 for noninferiority); the results were similar in the "on-treatment" analysis (hazard ratio, 1.03; 95% CI, 0.91 to 1.17). The major secondary end point of a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 1059 patients in the saxagliptin group and in 1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P=0.66). More patients in the saxagliptin group than in the placebo group were hospitalized for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P=0.007). Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively). CONCLUSIONS: DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trials of HF outcomes with dapagliflozin and empagliflozin, enrolling up to 50% of participants with type 2 diabetes, report reduction in cardiovascular death and improvement of HF among patients with HF with reduced ejection fraction and HF with preserved ejection fraction, respectively, independent of diabetes status, compared with placebo.66–69,88”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of SAVOR-TIMI 53 (NCT01107886) and EXAMINE (NCT00968708) were recently released and showed no increased risk of cardiovascular events with the DPP-4 inhibitors saxagliptin96 and alogliptin97, respectively.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [19]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Self-citationThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Cited by
Items 801–900 of 1,020
Bethel, M. A., Green, J. B., Milton, J., Tajar, A., Engel, S. S., Califf, R. M., Holman, R. R., & on behalf of the TECOS Executive Committee (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12441 · Cited by 46
“Two other recently reported DPP-4 CV outcomes trials, the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial (EXAMINE, NCT00968708) [27] and the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction trial (SAVOR-T…”
ResultUse of incretin agents and risk of pancreatic cancer: a population‐based cohort study
Knapen, L. M., van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G. M., Croes, S., Neef, C., de Vries, F., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12605 · Cited by 43
“1 years) there were five cases of pancreatic cancer in the saxagliptin arm and 12 in the comparator agent arm, while no events of pancreatic cancer were reported in the alogliptin or placebo arm of the EXAMINE cardiovascular outcome trial (n= 5380, median follow-up 18 months) [12,13].”
BackgroundTanabe, M., Motonaga, R., Terawaki, Y., Nomiyama, T., & Yanase, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12567 · Cited by 47
Kim, Y., Yoon, D., Park, S.-Y., Han, S. J., Kim, D. J., Lee, K. W., Park, R. W., & Kim, H. J. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.003957 · Cited by 48
Lim, S. K., Eckel, R. H., & Koh, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.013 · Cited by 48
Gomez-Peralta, F., Escalada San Martín, F. J., Menéndez Torre, E., Mata Cases, M., Ferrer García, J. C., Ezkurra Loiola, P., Ávila Lachica, L., Fornos Pérez, J. A., Artola Menéndez, S., Álvarez-Guisasola, F., et al. (2018) · Endocrinología, Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.004 · Cited by 39
“753 53,0 Sobrepeso (IMC > 28kg/m(2)) y GPA > 108 mg/dL y ≤270 mg/dL 10,7 7,2 % 7,7% 0,7** (5-48) 0.”
National Trends in Diabetes Medication Use in the United States: 2008 to 2015
Raval, A. D., & Vyas, A. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018815048 · Cited by 45
“However, the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 study published in 2013 showed an increased risk of heart failure with a DPP-4 inhibitor, saxagliptin among diabetes patients.(24) Consistent with the reporting, we…”
ResultSavarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Self-citationSinclair, A. J., Pennells, D., & Abdelhafiz, A. H. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02142-8 · Cited by 48
Avogaro, A., Dardano, A., de Kreutzenberg, S. V., & Prato, S. D. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12319 · Cited by 49
“More information can be drawn from two intervention trials, namely the Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (SAVOR-TIMI) and Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trials [81,82].”
MethodResultIncretin-Based Therapy for Prevention of Diabetic Vascular Complications
Mima, A. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1379274 · Cited by 48
Howse, P. M., Chibrikova, L., Twells, L., Barrett, B. J., & Gamble, J. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.06.014 · Cited by 47
Wang, A., Tang, H., Zhang, N., & Feng, X. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109080 · Cited by 46
Darsalia, V., Larsson, M., Nathanson, D., Klein, T., Nyström, T., & Patrone, C. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.17 · Cited by 44
Shore, A. C., Colhoun, H. M., Natali, A., Palombo, C., Östling, G., Aizawa, K., Kennbäck, C., Casanova, F., Persson, M., Gooding, K. M., et al. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12359 · Cited by 48
The metabolic vascular syndrome - guide to an individualized treatment
Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 50
Manrique, C. M., Habibi, J., Aroor, A. R., Sowers, J. R., Jia, G., Hayden, M. R., Garro, M., Martinez‐Lemus, L. A., Ramirez‐Perez, F. I., Klein, T., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0414-5 · Cited by 47
“In the SAVOR-TIMI 53 trial the use of saxagliptin was associated with increased risk of heart failure [58].”
MethodUse of incretin agents and risk of acute and chronic pancreatitis: A population‐based cohort study
Knapen, L. M., de Jong, R. G. P. J., Driessen, J. H. M., Keulemans, Y. C. A., van Erp, N. P., Bruin, M. L. D., Leufkens, H. G. M., Croes, S., & de Vries, F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12833 · Cited by 46
“1 years) and EXAMINE (n = 5380, median follow-up 18 months) cardiovascular outcome trials the cases of acute and chronic pancreatitis were similar in the saxagliptin and alogliptin arms as compared with the comparator agent arm.(36,37) The results of observational studies regarding the risk of pancreatitis remain KNAP…”
ResultDey, J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1307081 · Cited by 47
“[66,67], the EXAMINE trial (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) [68], and TECOS [69].”
MethodDo the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores, E., Santos‐Gallego, C. G., Mejia, N. M. D., & Badimón, J. J. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6786-x · Cited by 47
“In fact, the possible association of some DPP-4 inhibitors like saxagliptin and alogliptin with a higher risk for HF has generated regulatory warnings [26, 27].”
BackgroundCarbone, S., Dixon, D. L., Buckley, L. F., & Abbate, A. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.018 · Cited by 46
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later
McGuire, D. K., Marx, N., Johansen, O. E., Inzucchi, S. E., Rosenstock, J., & George, J. T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13645 · Cited by 42
Self-citationOkabe, K., Matsushima, S., Ikeda, S., Ikeda, M., Ishikita, A., Tadokoro, T., Enzan, N., Yamamoto, T., Sada, M., Deguchi, H., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14400 · Cited by 46
Giugliano, D., Bellastella, G., Longo, M., Scappaticcio, L., Maiorino, M. I., Chiodini, P., & Esposito, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14047 · Cited by 43
Royston, P. J., & Parmar, M. (2020) · Trials · doi:10.1186/s13063-020-4153-2 · Cited by 44
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 61
Effect of metformin on outcomes of catheter ablation for atrial fibrillation
Deshmukh, A., Ghannam, M., Liang, J. J., Saeed, M., Cunnane, R. T., Ghanbari, H., Latchamsetty, R., Crawford, T. C., Batul, S. A., Chung, E. H., et al. (2021) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.14954 · Cited by 47
Causes and Risk Factors for Death in Diabetes
Cavallari, I., Bhatt, D. L., Steg, P. G., Leiter, L. A., McGuire, D. K., Mosenzon, O., Im, K., Raz, I., Braunwald, E., & Scirica, B. M. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.030 · Cited by 51
Self-citationPredicting Cardiovascular Risk in Type 2 Diabetes: the Heterogeneity Challenges
Gore, M. O., McGuire, D. K., Lingvay, I., & Rosenstock, J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0607-7 · Cited by 48
Self-citationLiakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43
Mima, A., Gotoda, H., Lee, R., Murakami, A., Akai, R., & Lee, S. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100236 · Cited by 48
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c
Cavender, M. A., Scirica, B. M., Raz, I., Steg, P. G., McGuire, D. K., Leiter, L. A., Hirshberg, B., Davidson, J. A., Cahn, A., Mosenzon, O., et al. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.09.022 · Cited by 43
“The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)Thrombolysis in Myocardial Infarction (TIMI) 53 trial evaluated the cardiovascular safety and efficacy of saxagliptin, a selective dipeptidyl peptidase-4 inhibitor, vs placebo in 16,492 patients with type 2 diabetes.(12-…”
MethodSelf-citationGroop, P., Cooper, M. E., Perkovic, V., Sharma, K., Schernthaner, G., Haneda, M., Hocher, B., Gordat, M., Cescutti, J., Woerle, H., et al. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115579002 · Cited by 46
Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study
Baltzis, D., Dushay, J. R., Loader, J., Wu, J. S., Greenman, R. L., Roustit, M., & Veves, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2655 · Cited by 46
Shigiyama, F., Kumashiro, N., Miyagi, M., Iga, R., Kobayashi, Y., Kanda, E., Uchino, H., & Hirose, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12587 · Cited by 45
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure
Kosiborod, M., Gause‐Nilsson, I. A. M., Xu, J. L., Sonesson, C., & JOHNSSON, E. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.001 · Cited by 46
Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence
Leonard, C. E., Hennessy, S., Han, X., Siscovick, D. S., Flory, J., & Deo, R. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.04.003 · Cited by 45
Darsalia, V., Klein, T., Nyström, T., & Patrone, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.022 · Cited by 43
What have we learnt from “real world” data, observational studies and meta‐analyses
Chatterjee, S., Davies, M. J., & Khunti, K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13178 · Cited by 43
West, T. M., Wang, Q., Deng, B., Zhang, Y., Barbagallo, F., Reddy, G. R., Chen, D., Phan, K. S., Xu, B. Y., Isidori, A. M., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012273 · Cited by 43
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Liu, B., Wang, Y., Zhang, Y., & Yan, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828161409 · Cited by 45
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, W., Xu, L., Zhang, H., & Li, Y. (2022) · BMJ · doi:10.1136/bmj-2021-068882 · Cited by 50
Ryder, R. E. J. (2013) · Diabetic Medicine · doi:10.1111/dme.12301 · Cited by 41
Standl, E., Erbach, M., & Schnell, O. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0353-y · Cited by 44
Alvarez, C., Lingvay, I., Vuylsteke, V., Koffarnus, R. L., & McGuire, D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.143 · Cited by 46
“007).(73,74) Although not achieving statistical significance, the incidence of incident HF reported in EXAMINE was also numerically greater with alogliptin vs.”
BackgroundMethodSelf-citationPotentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus
Groeneveld, O. N., Kappelle, L. J., & Biessels, G. J. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12420 · Cited by 43
Ihara, M., Asanuma, H., Yamazaki, S., Kato, H., Asano, Y., Shinozaki, Y., Mori, H., Minamino, T., Asakura, M., Sugimachi, M., et al. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00835.2014 · Cited by 42
“The recent large-scale clinical trials EXAMINE and SAVOR showed that alogliptin does not reduce the rate of hospitalization or death due to CVD in patients with diabetes mellitus (42, 47).”
BackgroundWewer Albrechtsen, N. J., Albrechtsen, R., Bremholm, L., Svendsen, B., Kuhre, R. E., Poulsen, S. S., Christiansen, C. B., Jensen, E. P., Janus, C., Hilsted, L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.051 · Cited by 40
“…(which elevate levels of endogenous GLP-1), all showing non-significant changes in acute pancreatitis rates as compared to placebo treatment control groups, albeit with a numerical imbalance in some studies (Scirica et al., 2013; White et al., 2013; Green et al., 2015; Bentley-Lewis et al., 2015).”
ResultLei, Y., Hu, L., Yang, G., Piao, L., Jin, M., & Cheng, X. W. (2017) · Circulation Journal · doi:10.1253/circj.cj-16-1326 · Cited by 45
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2017.12.003 · Cited by 47
Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
Kitaura, H., Ogawa, S., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Pramusita, A., Kinjo, R., Ma, J., Kanou, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126578 · Cited by 45
Adapting Medication for Type 2 Diabetes to a Low Carbohydrate Diet
Cucuzzella, M. T., Riley, K., & Isaacs, D. M. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.688540 · Cited by 47
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 44
“The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus‐Thrombolysis in Myocardial Infarction trial studied the cardiovascular safety and efficacy of saxagliptin.(90) It demonstrated neutral effects of saxagliptin,”
Hupfeld, C., & Mudaliar, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13740 · Cited by 41
Bjornstad, P., Greasley, P. J., Wheeler, D. C., Chertow, G. M., Langkilde, A. M., Heerspink, H. J. L., & van Raalte, D. H. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.003 · Cited by 42
“(10) By comparison, studies assessing the cardiovascular effects of glucose lowering per se, when mediated by other agents, had not demonstrated similar benefits, while HF outcomes may even be worsened by some glucose-lowering drugs.(11, 12) Since publication of the results of several these and other cardiovascular sa…”
ResultShao, D.-W., Zhao, L.-J., & Sun, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116464 · Cited by 41
Son, J. W., & Kim, S. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.5.373 · Cited by 45
Zhu, X., Gillespie, D. G., & Jackson, E. K. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00070.2015 · Cited by 44
Tanaka, A., Inoue, T., Kitakaze, M., Oyama, J.-I., Sata, M., Taguchi, I., Shimizu, W., Watada, H., Tomiyama, H., Ako, J., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0381-x · Cited by 43
“placebo) demonstrated recently a significantly higher incidence of hospitalization for heart failure in the saxagliptin group, compared to placebo [43].”
Li, L., Li, S., Liu, J., Deng, K., Busse, J. W., Vandvik, P. O., Wong, E. M., Sohani, Z. N., Bała, M. M., Rios, L. P., et al. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0260-0 · Cited by 41
“These concerns followed publication of studies that reported increased risk of hospitalization for heart failure in patients using DPP-4 inhibitors [8–10].”
BackgroundElgendy, I. Y., Mahmoud, A. N., Barakat, A. F., Elgendy, A. Y., Saad, M. S., Abu‐Zaid, A., Wayangankar, S. A., & Bavry, A. A. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0208-x · Cited by 42
“In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)– Thrombolysis in Myocardial Infarction (TIMI) 53 trial, saxagliptin neither increased nor decreased the composite of cardiovascular death, myocardial infarction, or ischemic stroke compared with placebo [6].”
InfluentialThe cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
Secrest, M. H., Udell, J. A., & Filion, K. B. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.01.009 · Cited by 42
“The SAVOR-TIMI 53 trial examined saxagliptin for the primary endpoint of major adverse cardiovascular events (MACE), a composite of cardiovascular death, non-fatal MI, and non-fatal stroke (Table 1) [5-8].”
InfluentialSelf-citationWang, M.-T., Lin, S., Tang, P., Hung, W.-T., Cheng, C.-C., Yang, J.-S., Chang, H., Liu, C., Mar, G.-Y., & Huang, W. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0572-0 · Cited by 41
“ACEI: angiotensin‑converting enzyme inhibitor; ACS: acute coronary syn‑ drome; AMI: acute myocardial infarction; ARB: angiotensin receptor blocker; CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes; CCB: calcium channel blocker; CI: confidence interval; COPD: chr…”
BackgroundNovel therapies for diabetic kidney disease
Cherney, D. Z. I., & Bakris, G. L. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.005 · Cited by 48
Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review
Cehic, M. G., Nundlall, N., Greenfield, J. R., & Macdonald, P. S. (2018) · Journal of Transplantation · doi:10.1155/2018/1025893 · Cited by 43
Leiter, L. A., Shestakova, M. V., & Satman, İ. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0331-8 · Cited by 48
Self-citationGiugliano, D., Chiodini, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01047-0 · Cited by 43
Tanaka, M., Matsuo, Y., Yamakage, H., Masuda, S., Terada, Y., Muranaka, K., Wada, H., Hasegawa, K., Shimatsu, A., & Satoh‐Asahara, N. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.009 · Cited by 42
Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0385-y · Cited by 45
“In addition, no increase in the risk of pancreatitis, pancreatic cancer and/or cancer was seen with alogliptin [56] or saxagliptin [66] in the EXAMINE [56] and SAVOR-TIMI 53 [66] trials.”
BackgroundMethodComparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE
Cornell, S. A. (2017) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2016.11.005 · Cited by 47
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus: A Role in Cardiovascular Disease
Smilowitz, N. R., Donnino, R. M., & Schwartzbard, A. Z. (2014) · Circulation · doi:10.1161/circulationaha.113.006985 · Cited by 44
Velez, M., Peterson, E. L., Wells, K., Swadia, T., Sabbah, H. N., Williams, L. K., & Lanfear, D. E. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.10.012 · Cited by 39
“Recently completed randomized controlled trials have shown that DPP-4 inhibitors saxagliptin and alogliptin do not have a significant impact on major adverse cardiac events related to atherosclerotic CV disease (14, 15).”
BackgroundResultBlood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies
Lovshin, J. A., & Zinman, B. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.05.001 · Cited by 42
“The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction-53 trial (SAVOR-TIMI 53) (49) enrolled 16 494 patients with type 2 diabetes (median duration 10 years, mean A1C 8.”
Effect of Dipeptidyl Peptidase 4 Inhibition on Arterial Blood Pressure Is Context Dependent
Jackson, E. K., Mi, Z., Tofovic, S. P., & Gillespie, D. G. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04631 · Cited by 40
Alhadramy, M. S. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.02.001 · Cited by 55
“51).(98) Although this study revealed no increase in ischaemic events, it raised concerns about cardiovascular safety.”
BackgroundSagara, M., Suzuki, K., Aoki, C., Tanaka, S., Taguchi, I., Inoue, T., & Aso, Y. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0396-3 · Cited by 43
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dcs15-3005 · Cited by 43
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Waldrop, G. E., Zhong, J., Peters, M. C., Goud, A., Chen, Y., Davis, S. N., Mukherjee, B., & Rajagopalan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.08.018 · Cited by 41
Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
Tanaka, A., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.019 · Cited by 42
“However, in the SAVOR-TIMI 53 trial (saxagliptin) increased risk of hospitalization for heart failure (HF) as a secondary endpoint was unexpectedly found in patients who received saxagliptin treatment [30,33], although whether DPP-4 inhibitors contribute to the increased risk of worsened HF and the mechanisms are yet…”
Cardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 45
Consoli, A., Formoso, G., Baldassarre, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 37
“Among treatment for diabetes, thiazolidinediones have been shown to be associated with an increased risk of hospitalization for HF and a similar trend emerged from the safety CVOTs conducted with saxagliptin and (to a lesser extent) with alogliptin [35,36].”
ResultThe European Medicines Agency's approval of new medicines for type 2 diabetes
BLIND, E., Janssen, H., Dunder, K., & de Graeff, P. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13349 · Cited by 49
Heo, C. U., & Choi, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030393 · Cited by 43
Addressing Comorbidities in Heart Failure
Bavishi, A. A., & Patel, R. B. (2020) · Heart Failure Clinics · doi:10.1016/j.hfc.2020.06.005 · Cited by 50
Xie, Y., Bowe, B., Gibson, A. K., McGill, J. B., Yan, Y., Maddukuri, G., & Al-Aly, Z. (2020) · Diabetes Care · doi:10.2337/dc20-1231 · Cited by 40
Lau, E. S., Braunwald, E., Morrow, D. A., Giugliano, R. P., Antman, E. M., Gibson, C. M., Scirica, B. M., Bohula, E. A., Wiviott, S. D., Bhatt, D. L., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052339 · Cited by 43
Self-citationCellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy
Dannenberg, L., Weske, S., Kelm, M., Levkau, B., & Polzin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107920 · Cited by 43
(2014) · Diabetes Care · doi:10.2337/dc15-s013 · Cited by 41
DPP-4 Inhibitor–Related Pancreatitis: Rare but Real!
DeVries, J. H., & Rosenstock, J. (2017) · Diabetes Care · doi:10.2337/dci16-0035 · Cited by 39
Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
Dardano, A., Miccoli, R., Bianchi, C., Daniele, G., & Prato, S. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108112 · Cited by 41
Guo, Y., Zhang, J., Sun, J., & Gao, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116185 · Cited by 42
The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
Panchapakesan, U., & Pollock, C. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00443 · Cited by 39
“This study enrolled 16,492 patients with type 2 diabetes with a history of, or were at risk for, cardiovascular events and followed up for a median of 2.1 years (41) .”
BackgroundInfluentialWaumans, Y., Vliegen, G., Maes, L., Rombouts, M., Declerck, K., der Veken, P. V., Berghe, W. V., Meyer, G. R. Y. D., Schrijvers, D. M., & Meester, I. D. (2015) · Inflammation · doi:10.1007/s10753-015-0263-5 · Cited by 44
“Moreover, in recent years, DPP4 inhibitors have stirred some interest as they might improve atherosclerotic disease [29], although recent reports suggest that DPP4inhibitors may rather increase the risk of heart failure [30, 31].”
BackgroundKim, S. C., Glynn, R. J., Liu, J., Everett, B. M., & Goldfine, A. B. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0663-2 · Cited by 42
“Our finding of no increased CVD risk in DPP4i initiators as used in the community is consistent with RCT data on linagliptin, saxagliptin, and alogliptin [4, 11, 12, 25].”
ResultDel Prato, S., Foley, J. E., Kothny, W., Kozlovski, P., Stumvoll, M., Paldánius, P. M., & Matthews, D. R. (2014) · Diabetic Medicine · doi:10.1111/dme.12508 · Cited by 39
Teneligliptin: expectations for its pleiotropic action
Morishita, R., & Nakagami, H. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1000301 · Cited by 41
“The large-scale SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus--Thrombolysis in Myocardial Infarction) trial included 16,492 T2DM patients who had a history of or were at risk for cardiovascular events [15].”
MethodManagement of Hyperglycemia in Type 2 Diabetes, 2015: A Patient- Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., & Wender, R. C. (2015) · Cited by 44
SGLT2 inhibition and heart failure—current concepts
da Silva, J. C., Durães, A. R., Abreu, M., Rocha, N. A., & Roever, L. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9703-2 · Cited by 44
Metadata
- Authors
- Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., & Raz, I.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- AstraZeneca (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Hadassah Medical Center (IL)
- St George's, University of London (GB)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1317-1326
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2064130493
- Cited by
- 3,470
- References
- 38
- Citations by year
- 2026: 82 · 2025: 137 · 2024: 129 · 2023: 157 · 2022: 182 · 2021: 233 · 2020: 322 · 2019: 324 · 2018: 365 · 2017: 392 · 2016: 422 · 2015: 337 · 2014: 320 · 2013: 57
- FWCI
- 297.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion)
- Hispana (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Griffith Research Online (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- saxagliptin, type 2 diabetes, DPP-4 inhibitors, cardiovascular safety, cardiovascular outcomes, myocardial infarction, ischemic stroke, cardiovascular mortality, heart failure hospitalization, pancreatitis, non-inferiority, antidiabetic drugs, cardiovascular risk stratification, glycemic control
- MeSH terms
- Adamantane, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptides, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Kaplan-Meier Estimate, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.